Published in PLoS One on October 27, 2011
Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53. Nature (2016) 0.93
Triptolide induces growth inhibition and apoptosis of human laryngocarcinoma cells by enhancing p53 activities and suppressing E6-mediated p53 degradation. PLoS One (2013) 0.85
Biological basis for increased sensitivity to radiation therapy in HPV-positive head and neck cancers. Biomed Res Int (2014) 0.84
Rotavirus-encoded nonstructural protein 1 modulates cellular apoptotic machinery by targeting tumor suppressor protein p53. J Virol (2013) 0.82
A High-Throughput Cell-Based Screen Identified a 2-[(E)-2-Phenylvinyl]-8-Quinolinol Core Structure That Activates p53. PLoS One (2016) 0.75
Analysis of ROC: The value of HPV16 E6 protein in the diagnosis of early stage cervical carcinoma and precancerous lesions. Oncol Lett (2016) 0.75
MiR-23b controls ALDH1A1 expression in cervical cancer stem cells. BMC Cancer (2017) 0.75
The potential role of infectious agents and pelvic inflammatory disease in ovarian carcinogenesis. Infect Agent Cancer (2017) 0.75
Mdm2 promotes the rapid degradation of p53. Nature (1997) 21.26
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell (1990) 20.60
A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell (1992) 19.87
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell (1992) 16.53
Participation of p53 protein in the cellular response to DNA damage. Cancer Res (1991) 16.00
Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science (1994) 13.51
Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science (1990) 12.88
The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell (1993) 12.41
Suppression of human colorectal carcinoma cell growth by wild-type p53. Science (1990) 11.18
Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science (1996) 9.48
Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer (2004) 6.67
p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol (1990) 5.20
Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. Mol Cell Biol (1993) 4.04
The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev (1993) 3.99
In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res (1996) 3.50
p53 polymorphisms: cancer implications. Nat Rev Cancer (2009) 3.33
p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res (1993) 2.99
Rescuing the function of mutant p53. Nat Rev Cancer (2001) 2.95
Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor. Science (1996) 2.56
SOFAST-HMQC experiments for recording two-dimensional heteronuclear correlation spectra of proteins within a few seconds. J Biomol NMR (2005) 2.53
Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene (1999) 2.43
COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. EMBO J (2001) 2.41
Heterochromatin silencing of p53 target genes by a small viral protein. Nature (2010) 2.12
Dual-site regulation of MDM2 E3-ubiquitin ligase activity. Mol Cell (2006) 2.09
The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells. J Biol Chem (1998) 2.07
Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene (1994) 1.94
The E6 and E7 genes of HPV-18 are sufficient for inducing two-stage in vitro transformation of human keratinocytes. Oncogene (1989) 1.94
How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression? Cell Death Differ (2007) 1.84
Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J (1996) 1.82
Hot-spot mutants of p53 core domain evince characteristic local structural changes. Proc Natl Acad Sci U S A (1999) 1.73
Structural and functional analysis of E6 oncoprotein: insights in the molecular pathways of human papillomavirus-mediated pathogenesis. Mol Cell (2006) 1.67
The central region of HDM2 provides a second binding site for p53. Proc Natl Acad Sci U S A (2006) 1.67
An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene (2001) 1.66
Phosphorylation site interdependence of human p53 post-translational modifications in response to stress. J Biol Chem (2003) 1.63
Mutant conformation of p53. Precise epitope mapping using a filamentous phage epitope library. J Mol Biol (1992) 1.62
Inhibition of p53 DNA binding by human papillomavirus E6 proteins. J Virol (1994) 1.54
The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo. J Biol Chem (2002) 1.50
High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation. J Virol (1996) 1.42
Characterization of human hect domain family members and their interaction with UbcH5 and UbcH7. J Biol Chem (1998) 1.36
Dynamics in the p53-Mdm2 ubiquitination pathway. Cell Cycle (2004) 1.33
MDM2-dependent ubiquitination of nuclear and cytoplasmic P53. Oncogene (2000) 1.33
Intracellular localization and DNA-binding properties of human papillomavirus type 18 E6 protein expressed with a baculovirus vector. J Virol (1989) 1.28
CRINEPT-TROSY NMR reveals p53 core domain bound in an unfolded form to the chaperone Hsp90. Proc Natl Acad Sci U S A (2002) 1.17
Identification of a sequence element from p53 that signals for Mdm2-targeted degradation. Mol Cell Biol (2000) 1.14
Solution structure determination and mutational analysis of the papillomavirus E6 interacting peptide of E6AP. Biochemistry (2001) 1.01
Tip110, the human immunodeficiency virus type 1 (HIV-1) Tat-interacting protein of 110 kDa as a negative regulator of androgen receptor (AR) transcriptional activation. J Biol Chem (2004) 0.99
The domain of p53 required for binding HPV 16 E6 is separable from the degradation domain. Oncogene (1995) 0.98
The 'wildtype' conformation of p53: epitope mapping using hybrid proteins. Oncogene (2001) 0.96
Mdm2 binding to a conformationally sensitive domain on p53 can be modulated by RNA. FEBS Lett (2000) 0.95
Identification of a region of p53 that confers lability. J Biol Chem (1996) 0.93
HPV-18 E6 mediated inhibition of p53 DNA binding activity is independent of E6 induced degradation. Oncogene (1995) 0.92
Definition of a major p53 binding site on Ad2E1B58K protein and a possible nuclear localization signal on the Ad12E1B54K protein. Oncogene (1999) 0.91
Targetting of the N-terminal domain of the human papillomavirus type 16 E6 oncoprotein with monomeric ScFvs blocks the E6-mediated degradation of cellular p53. J Mol Recognit (2000) 0.89
Ubiquitination and proteasome degradation of the E6 proteins of human papillomavirus types 11 and 18. J Gen Virol (2004) 0.89
A sequence element of p53 that determines its susceptibility to viral oncoprotein-targeted degradation. Oncogene (2001) 0.85
ELM: the status of the 2010 eukaryotic linear motif resource. Nucleic Acids Res (2009) 2.59
How viruses hijack cell regulation. Trends Biochem Sci (2010) 1.93
Structural basis of BACH1 phosphopeptide recognition by BRCA1 tandem BRCT domains. Structure (2004) 1.82
Structural and functional analysis of E6 oncoprotein: insights in the molecular pathways of human papillomavirus-mediated pathogenesis. Mol Cell (2006) 1.67
Reconstitution of yeast silent chromatin: multiple contact sites and O-AADPR binding load SIR complexes onto nucleosomes in vitro. Mol Cell (2009) 1.61
Molecular basis for the association of human E4B U box ubiquitin ligase with E2-conjugating enzymes UbcH5c and Ubc4. Structure (2010) 1.58
A pilot randomized controlled trial comparing bismuth iodine paraffin paste external ear pack and no ear pack after middle ear surgery. Eur Arch Otorhinolaryngol (2013) 1.38
Radiation response: an additional unique signature of myxoid liposarcoma. Int J Radiat Oncol Biol Phys (2004) 1.34
Solution structure analysis of the HPV16 E6 oncoprotein reveals a self-association mechanism required for E6-mediated degradation of p53. Structure (2012) 1.30
Structural basis for hijacking of cellular LxxLL motifs by papillomavirus E6 oncoproteins. Science (2013) 1.22
Expression of the CUB domain containing protein 1 (CDCP1) gene in colorectal tumour cells. FEBS Lett (2007) 1.16
The emerging contribution of sequence context to the specificity of protein interactions mediated by PDZ domains. FEBS Lett (2012) 1.12
Kinetic analysis of the interactions of human papillomavirus E6 oncoproteins with the ubiquitin ligase E6AP using surface plasmon resonance. J Mol Biol (2005) 1.10
Discovery of candidate KEN-box motifs using cell cycle keyword enrichment combined with native disorder prediction and motif conservation. Bioinformatics (2008) 1.09
Degradation of p53 by human Alphapapillomavirus E6 proteins shows a stronger correlation with phylogeny than oncogenicity. PLoS One (2010) 1.09
E6 proteins from diverse papillomaviruses self-associate both in vitro and in vivo. J Mol Biol (2009) 1.05
alpha-Synuclein modulation of Ca2+ signaling in human neuroblastoma (SH-SY5Y) cells. J Neurochem (2009) 1.02
Formation of well-defined soluble aggregates upon fusion to MBP is a generic property of E6 proteins from various human papillomavirus species. Protein Expr Purif (2006) 1.00
Binding of human papillomavirus 16 E6 to p53 and E6AP is impaired by monoclonal antibodies directed against the second zinc-binding domain of E6. J Gen Virol (2005) 0.98
The mental health and wellbeing of children and adolescents in home-based foster care. Med J Aust (2007) 0.98
Domain substructure of HPV E6 oncoprotein: biophysical characterization of the E6 C-terminal DNA-binding domain. Biochemistry (2003) 0.97
Venous thromboembolism in medical inpatients--the silent epidemic of neglect. J R Soc Med (2005) 0.97
Elbow injuries at the London 2012 Summer Olympic Games: demographics and pictorial imaging review. AJR Am J Roentgenol (2013) 0.96
Adductor-related groin pain in competitive athletes. Role of adductor enthesis, magnetic resonance imaging, and entheseal pubic cleft injections. J Bone Joint Surg Am (2007) 0.96
Identification of unusual E6 and E7 proteins within avian papillomaviruses: cellular localization, biophysical characterization, and phylogenetic analysis. J Virol (2009) 0.95
Preferential nuclear localization of the human papillomavirus type 16 E6 oncoprotein in cervical carcinoma cells. J Gen Virol (2003) 0.93
Comparative analysis of virus-host interactomes with a mammalian high-throughput protein complementation assay based on Gaussia princeps luciferase. Methods (2012) 0.93
Putting into practice domain-linear motif interaction predictions for exploration of protein networks. PLoS One (2011) 0.92
Prevention of type 2 diabetes induced by high fat diet in the C57BL/6J mouse by two medicinal plants used in traditional treatment of diabetes in the east of Algeria. J Ethnopharmacol (2010) 0.91
Intracellular scFvs against the viral E6 oncoprotein provoke apoptosis in human papillomavirus-positive cancer cells. Biochem Biophys Res Commun (2007) 0.90
Capturing protein-protein complexes at equilibrium: the holdup comparative chromatographic retention assay. Protein Expr Purif (2006) 0.90
Adherence to anti-inflammatory treatment for asthma in clinical practice in France. Clin Ther (2008) 0.90
Nucleocytoplasmic shuttling of antigen in mammalian cells conferred by a soluble versus insoluble single-chain antibody fragment equipped with import/export signals. Exp Cell Res (2003) 0.90
Bilateral sequential cochlear implantation in the congenitally deaf child: evidence to support the concept of a 'critical age' after which the second ear is less likely to provide an adequate level of speech perception on its own. Cochlear Implants Int (2009) 0.89
Assessment of referrals into the soft tissue sarcoma service: evaluation of imaging early in the pathway process. Sarcoma (2012) 0.89
Surface plasmon resonance analysis of the binding of high-risk mucosal HPV E6 oncoproteins to the PDZ1 domain of the tight junction protein MAGI-1. J Mol Recognit (2010) 0.88
Life-threatening adverse drug reactions at admission to medical intensive care: a prospective study in a teaching hospital. Intensive Care Med (2007) 0.87
The structural and dynamic response of MAGI-1 PDZ1 with noncanonical domain boundaries to the binding of human papillomavirus E6. J Mol Biol (2011) 0.87
Concordance between prescriber- and patient-reported previous medical history and NSAID indication in the CADEUS cohort. Pharmacoepidemiol Drug Saf (2010) 0.87
Improving patient safety: the comparative views of patient-safety specialists, workforce staff and managers. BMJ Qual Saf (2011) 0.86
Strategies for bacterial expression of protein-peptide complexes: application to solubilization of papillomavirus E6. Protein Expr Purif (2011) 0.86
Locomotor and geotactic behavior of Drosophila melanogaster over-expressing neprilysin 2. Peptides (2008) 0.86
The mRNA-binding site of annexin A2 resides in helices C-D of its domain IV. J Mol Biol (2007) 0.86
Phage display can select over-hydrophobic sequences that may impair prediction of natural domain-peptide interactions. Bioinformatics (2011) 0.85
Adductor-related groin pain in recreational athletes: role of the adductor enthesis, magnetic resonance imaging, and entheseal pubic cleft injections. J Bone Joint Surg Am (2009) 0.84
Omalizumab-induced decrease of FcξRI expression in patients with severe allergic asthma. Respir Med (2010) 0.84
1H and 15N resonance assignment, secondary structure and dynamic behaviour of the C-terminal domain of human papillomavirus oncoprotein E6. J Biomol NMR (2005) 0.84
PIN-G--a novel reporter for imaging and defining the effects of trafficking signals in membrane proteins. BMC Biotechnol (2006) 0.83
TRAF4 is a novel phosphoinositide-binding protein modulating tight junctions and favoring cell migration. PLoS Biol (2013) 0.83
Sonographic evaluation of injuries to the pectoralis muscles. AJR Am J Roentgenol (2005) 0.83
Treatment of high fat diet induced type 2 diabetes in C57BL/6J mice by two medicinal plants used in traditional treatment of diabetes in the east of Algeria. J Ethnopharmacol (2010) 0.83
Double posterior labyrinthotomy technique: results in three Med-El patients with common cavity. Otol Neurotol (2005) 0.83
Partial rupture of the distal semitendinosus tendon treated by tenotomy--a previously undescribed entity. Knee (2005) 0.82
Imaging of the acetabular labrum. Semin Musculoskelet Radiol (2013) 0.82
Subacute posteromedial impingement of the ankle in athletes: MR imaging evaluation and ultrasound guided therapy. Skeletal Radiol (2005) 0.82
Identification using phage display of peptides promoting targeting and internalization into HPV-transformed cell lines. J Mol Recognit (2005) 0.82
Magnetization transfer imaging shows tissue abnormalities in the reversible penumbra. Stroke (2007) 0.82
Physicochemical characteristics and bronchial epithelial cell cytotoxicity of Folpan 80 WG(R) and Myco 500(R), two commercial forms of folpet. Part Fibre Toxicol (2007) 0.82
Clinical grade OK432-activated dendritic cells: in vitro characterization and tracking during intralymphatic delivery. J Immunother (2009) 0.81
Comparative properties of two peptide-antibody interactions as deduced from epitope delineation. J Immunol Methods (2002) 0.81
Performance of the standardised MedDRA® queries for case retrieval in the French spontaneous reporting database. Drug Saf (2014) 0.80
Surface expression and distribution of voltage-gated potassium channels in neurons (Review). Mol Membr Biol (2008) 0.80
Parenting is a mental health issue. Australas Psychiatry (2004) 0.80
Prevalence and associated factors of oropharyngeal side effects in users of inhaled corticosteroids in a real-life setting. J Aerosol Med Pulm Drug Deliv (2010) 0.79
Engineering, biophysical characterisation and binding properties of a soluble mutant form of annexin A2 domain IV that adopts a partially folded conformation. J Mol Biol (2006) 0.79
Ankle impingement syndromes. Radiol Clin North Am (2008) 0.79
Prevalence of intrinsic disorder in the hepatitis C virus ARFP/Core+1/S protein. FEBS J (2010) 0.79
Measurement of hepatic arterial flow using phase contrast magnetic resonance imaging. Phys Med Biol (2009) 0.79
Common cavity and custom-made electrodes: speech perception and audiological performance of children with common cavity implanted with a custom-made MED-EL electrode. Int J Pediatr Otorhinolaryngol (2013) 0.79
Protein mutagenesis with monodispersity-based quality probing: selective inactivation of p53 degradation and DNA-binding properties of HPV E6 oncoprotein. Protein Expr Purif (2002) 0.78